List of Excipients in Branded Drug ZYNRELEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Heron Therapeutics Inc	ZYNRELEF	bupivacaine and meloxicam	47426-301	DETOSU/TRIETHYLENE GLYCOL/TRIETHYLENE GLYCOL POLYGLYCOLIDE COPOLYMER	2035-04-20
Heron Therapeutics Inc	ZYNRELEF	bupivacaine and meloxicam	47426-301	DIMETHYL SULFOXIDE	2035-04-20
Heron Therapeutics Inc	ZYNRELEF	bupivacaine and meloxicam	47426-301	MALEIC ACID	2035-04-20
Heron Therapeutics Inc	ZYNRELEF	bupivacaine and meloxicam	47426-301	TRIACETIN	2035-04-20

ZYNRELEF Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: September 2, 2026

ZYNRELEF is a dual-acting, extended-release postoperative analgesic that combines bupivacaine and meloxicam in a proprietary polymer-based delivery system. Its commercial value depends on more than the active ingredients. The excipient system controls local retention, drug release, viscosity, syringeability, sterility, storage, surgical application, and potential formulation barriers to generic entry.

The strongest commercial opportunities are in excipient supply, controlled-release formulation development, hospital economics, procedure-specific presentations, and international expansion. The principal risks are formulation replication, regulatory comparability, manufacturing scale-up, and substitution by lower-cost local anesthetics, liposomal bupivacaine, non-opioid analgesics, and alternative postoperative protocols.

What is ZYNRELEF and how does its formulation work?

ZYNRELEF is an extended-release solution containing bupivacaine and meloxicam. Pacira Pharmaceuticals developed the product for application into the surgical site during closure. The FDA approved ZYNRELEF in May 2021 for use in adults as a postsurgical analgesic for up to 72 hours after small- to medium-sized open abdominal procedures and total knee arthroplasty. The FDA later expanded the indication to include additional soft-tissue and orthopedic procedures.[1,2]

The product is supplied in two strengths:

Presentation	Bupivacaine	Meloxicam
Low strength	60 mg	1.8 mg
High strength	200 mg	6 mg

ZYNRELEF differs from conventional bupivacaine injections because it combines:

• Immediate local anesthetic activity from bupivacaine.
• Anti-inflammatory activity from meloxicam.
• Extended release from a polymer-based delivery vehicle.
• Direct application to the surgical site rather than systemic oral dosing alone.

The formulation is designed to remain at or near the application site and release the active ingredients over an extended period. This creates technical requirements that ordinary injectable excipients do not necessarily meet.

What excipients are used in ZYNRELEF?

The FDA prescribing information identifies sucrose acetate isobutyrate as a principal inactive ingredient in the delivery system. The product also contains benzyl alcohol and ethanol. The full formulation is proprietary, and the public label does not disclose every manufacturing parameter or the complete process design.[1]

Excipient or component	Likely formulation role	Commercial significance
Sucrose acetate isobutyrate	Biodegradable or bioerodible matrix and release-control component	Core differentiation and likely principal excipient barrier
Ethanol	Solvent or co-solvent supporting drug and polymer processing	Affects solubility, evaporation, viscosity, and manufacturing controls
Benzyl alcohol	Preservative or formulation-processing component	Raises concentration, toxicity, and route-of-administration considerations
Water and process solvents	Vehicle and manufacturing media	Affect stability, residual solvents, and sterilization strategy
Bupivacaine hydrochloride	Local anesthetic active ingredient	Controls immediate analgesic effect and systemic safety
Meloxicam	Nonsteroidal anti-inflammatory active ingredient	Provides anti-inflammatory analgesia and creates combination-product complexity

Sucrose acetate isobutyrate, commonly known as SAIB, is commercially used as a viscosity modifier, coating material, and delivery-system excipient. In ZYNRELEF, its value is not simply as an inactive ingredient. It is part of the release architecture. A substitute must match drug loading, local tolerability, injectability or applicator performance, degradation behavior, release kinetics, and surgical-site handling.

Why is sucrose acetate isobutyrate strategically important?

SAIB creates several formulation advantages:

1. It can support high drug loading in a relatively compact dosage form.
2. It can generate a viscous matrix that remains at the surgical site.
3. It can support sustained release without requiring a conventional implant.
4. It may reduce the need for complex microparticle or liposome manufacturing.
5. It creates a formulation-specific technical hurdle for generic developers.

The excipient strategy also creates constraints. High-viscosity systems can complicate:

• Sterile filtration.
• Aseptic filling.
• Vial and syringe compatibility.
• Dose uniformity.
• Temperature-controlled storage.
• Application through surgical instruments.
• Residual solvent control.
• Scale-up from laboratory mixing to commercial batch production.

A competing formulation using a different polymer, lipid, depot system, or in situ gel may avoid direct replication of the SAIB system. It would still need to demonstrate comparable clinical performance and satisfy FDA requirements for a combination product with extended local release.

What FDA regulatory issues affect ZYNRELEF excipient development?

ZYNRELEF is regulated as a drug product, but its delivery system creates drug-device and combination-product considerations. Excipient changes can affect the product’s critical quality attributes even when the active ingredients remain unchanged.

Key FDA concerns include:

Regulatory issue	Effect on ZYNRELEF or a competing product
Local tissue exposure	Requires assessment of tolerability, inflammation, necrosis, and wound healing
Systemic bupivacaine exposure	Limits dosage and affects cardiovascular and central nervous system safety
NSAID exposure	Raises renal, gastrointestinal, cardiovascular, bleeding, and wound-healing questions
Release profile	Must remain consistent across batches and presentations
Sterility assurance	Critical because the product is applied to a surgical site
Extractables and leachables	Relevant to vials, closures, applicators, and polymer-contact materials
Residual solvents	Particularly relevant where ethanol or other processing solvents are used
Container closure	Must preserve composition, sterility, and viscosity through shelf life
Stability	Must support the labeled storage period and temperature conditions

The FDA label states that ZYNRELEF is stored refrigerated and protected from freezing. This creates an opportunity for improved formulations with room-temperature stability, but any such change would require substantial stability, container-closure, and clinical comparability work.[1]

What commercial opportunities exist for ZYNRELEF excipients?

Excipient supply and dual sourcing

SAIB and formulation-grade solvent suppliers can target Pacira and its contract manufacturing network with:

• GMP-grade material.
• Tighter impurity specifications.
• Low-peroxide and low-water grades.
• Validated sterilization or bioburden-control processes.
• Dual-source qualification packages.
• Long-term supply agreements.
• Regional inventory and cold-chain support.

The most valuable supplier position is not commodity volume. It is qualified status in the commercial formulation. Once an excipient is embedded in a sterile extended-release product, replacement can require extensive comparability work and regulatory documentation.

Improved polymer systems

Competitors can develop alternative excipients that provide:

• Lower viscosity during filling.
• Better syringeability or applicator flow.
• Faster initial release followed by sustained delivery.
• More predictable degradation.
• Reduced local irritation.
• Room-temperature stability.
• Lower residual solvent burden.

Potential platforms include biodegradable polyesters, lipid depots, thermosensitive gels, injectable hydrogels, and solvent-exchange systems. The commercial opportunity is strongest where a platform can deliver comparable postoperative analgesia with simpler manufacturing or lower cost.

New surgical presentations

ZYNRELEF is applied to the surgical site. Commercial development could focus on procedure-specific delivery formats, including:

• Premeasured applicators.
• Dual-chamber devices.
• Ready-to-use sterile syringes.
• Cannula-based delivery systems.
• Procedure kits for orthopedic and abdominal surgery.
• Smaller presentations for ambulatory surgery centers.
• Larger presentations for high-volume orthopedic procedures.

A device or applicator that reduces preparation time, leakage, or dosing variability could improve hospital adoption without changing the active ingredients.

Hospital economic positioning

The product’s economic case depends on reducing opioid use, improving recovery, lowering nursing workload, shortening post-anesthesia care, and supporting outpatient surgery. Hospitals will compare ZYNRELEF with:

• Standard bupivacaine.
• Liposomal bupivacaine, including EXPAREL.
• Regional nerve blocks.
• Catheter-based local anesthetic infusion.
• Intravenous and oral multimodal analgesia.
• Generic meloxicam and short-acting local anesthetics.

The excipient system contributes to value only if it produces measurable clinical and operational benefits. A formulation with higher acquisition cost must support evidence of reduced rescue medication, improved ambulation, earlier discharge, or lower total episode cost.

How does ZYNRELEF compare with competing postoperative analgesics?

Product or approach	Delivery model	Duration objective	Excipient or technology barrier	Main competitive issue
ZYNRELEF	Bupivacaine plus meloxicam depot solution	Up to 72 hours	SAIB-based delivery system and manufacturing process	Cost and procedure-specific evidence
EXPAREL	Liposomal bupivacaine	Up to 72 hours	Liposome composition and manufacturing	Established hospital use and formulation IP
Standard bupivacaine	Immediate-release injection	Shorter duration	Limited formulation complexity	Low cost
Regional nerve block	Catheter or single-shot injection	Variable	Clinical technique and equipment	Provider expertise and workflow
Oral multimodal therapy	Systemic NSAID, acetaminophen, opioid where needed	Variable	Limited delivery-system IP	Low acquisition cost
Other depot systems	Polymer, gel, lipid, or implant	Extended	Platform-specific release technology	Clinical comparability and manufacturing scale

ZYNRELEF has a differentiated mechanism because it combines a local anesthetic with an NSAID in one extended-release product. EXPAREL has a more established liposomal delivery platform and a broader commercial history. Generic bupivacaine remains the principal price competitor.

What patents protect ZYNRELEF and its excipient system?

ZYNRELEF’s defensibility is expected to rest primarily on formulation, delivery, composition, method-of-use, and manufacturing claims rather than on basic patents covering bupivacaine or meloxicam. Those active ingredients are long-established and do not provide meaningful composition-of-matter exclusivity for the product.

Relevant patent categories include:

• Combinations of bupivacaine and meloxicam.
• Extended-release local administration.
• SAIB-containing delivery systems.
• Drug loading and concentration ranges.
• Surgical-site application methods.
• Release profiles and treatment durations.
• Specific procedures, including orthopedic and abdominal surgery.
• Manufacturing and mixing processes.
• Container or applicator configurations.

The FDA Orange Book is the controlling public source for patents listed against an approved drug product. Patent listings and expiration dates should be assessed by product strength, dosage form, and current Orange Book edition rather than inferred from the FDA approval date.[3] Patent-term adjustment, patent-term extension, terminal disclaimers, reissued patents, and litigation settlements can change the practical exclusivity position.

Because ZYNRELEF uses established active ingredients, a generic applicant could target the product through a formulation or method-of-use strategy. A Paragraph IV certification could challenge listed patents before their expiration. The commercial threat would depend on whether the applicant can avoid the key SAIB, combination, release-profile, and method claims.

When does ZYNRELEF lose exclusivity?

ZYNRELEF does not have a single exclusivity date. Its commercial protection consists of overlapping FDA regulatory exclusivity and patent rights.

Protection type	Relevance
New drug exclusivity	Applies to the original FDA approval and any qualifying regulatory period
New indication exclusivity	May attach to later approved uses if statutory requirements are met
Formulation patents	Can protect the delivery vehicle and composition
Method-of-use patents	Can protect specified surgical procedures or dosing methods
Manufacturing patents	May raise production barriers but are harder to enforce against an independently manufactured generic
Orange Book-listed patents	Can trigger a Paragraph IV notice and possible 30-month stay
Trade secrets	Can protect process parameters, scale-up conditions, and quality controls

A generic entrant could seek approval through an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements. Because extended-release local products can have complex release and local-exposure characteristics, the regulatory pathway may be more demanding than for conventional bupivacaine injection.

What Paragraph IV and litigation risks affect ZYNRELEF?

The principal generic risks are:

1. A formulation challenge that substitutes or modifies the SAIB delivery system.
2. A patent invalidity challenge against combination or release claims.
3. A noninfringement strategy based on different excipient concentrations.
4. A method-of-use challenge using a different surgical indication.
5. A 505(b)(2) application for a modified depot or administration system.
6. A separate product that combines bupivacaine with another anti-inflammatory agent.

Public commercial analysis should distinguish between an FDA filing, a Paragraph IV notice, actual ANDA litigation, and a launched product. These events have different timing and economic consequences. A patent lawsuit can delay approval without guaranteeing long-term market protection. A settlement may permit an authorized generic, licensed entry, or launch at a negotiated date.

No biosimilar pathway applies to ZYNRELEF because it is a chemically synthesized small-molecule drug product, not a biologic. The relevant follow-on risks are generic, 505(b)(2), formulation, and therapeutic substitution risks.

Which companies are positioned to challenge or compete with ZYNRELEF?

The competitive field includes:

• Generic injectable manufacturers with bupivacaine portfolios.
• Developers of long-acting local anesthetic depots.
• Companies commercializing liposomal or polymeric delivery platforms.
• Hospital-focused analgesic companies.
• Contract development and manufacturing organizations with sterile depot capabilities.
• Device companies offering surgical-site applicators.
• Manufacturers of multimodal postoperative pain products.

EXPAREL is the closest branded formulation competitor. Standard bupivacaine and generic meloxicam are the strongest low-cost substitutes. A new entrant does not need to replicate ZYNRELEF exactly if it can show equivalent clinical utility, easier administration, lower cost, or broader procedure coverage.

How strong is the ZYNRELEF patent estate?

The estate is strongest where four elements overlap:

• The bupivacaine-meloxicam combination.
• The SAIB-based or equivalent sustained-release matrix.
• Defined drug concentrations and release behavior.
• Surgical-site methods with measurable clinical outcomes.

Protection is weaker for broad claims that rely only on known active ingredients or generic postoperative pain treatment. Manufacturing claims can be commercially valuable but may be difficult to detect and enforce. Method-of-use claims can protect revenue in selected procedures, although their practical value depends on prescribing behavior and generic labeling.

The commercial durability of the estate will therefore depend on claim breadth, patent prosecution history, Orange Book listing strategy, and whether alternative excipients can deliver comparable performance without literal infringement.

Key Takeaways

• ZYNRELEF’s core differentiation is its extended-release bupivacaine-meloxicam delivery system.
• Sucrose acetate isobutyrate is the central publicly identified excipient and likely a major formulation-control element.
• Excipient suppliers can create value through qualified SAIB supply, impurity control, dual sourcing, and process support.
• The most attractive product opportunities are room-temperature-stable formulations, ready-to-use applicators, procedure-specific kits, and lower-cost alternative depot systems.
• Generic risk is driven by formulation, 505(b)(2), method-of-use, and manufacturing strategies rather than biosimilar competition.
• The FDA Orange Book and applicable patent records must be used to determine current listed patents, expiration dates, Paragraph IV exposure, and litigation risk.
• ZYNRELEF competes with EXPAREL, standard bupivacaine, regional anesthesia, and low-cost multimodal analgesia.
• Commercial adoption depends on total episode economics, not excipient technology alone.

FAQs about ZYNRELEF excipients and market opportunities

What is the main release-controlling excipient in ZYNRELEF?

Sucrose acetate isobutyrate is the principal publicly identified release-system excipient in ZYNRELEF.

Can a generic manufacturer use a different excipient from ZYNRELEF?

Yes. A follow-on manufacturer may pursue a different excipient system if it satisfies FDA requirements and does not infringe applicable formulation, composition, method, or manufacturing patents.

Is ZYNRELEF a biologic eligible for biosimilar competition?

No. ZYNRELEF is a small-molecule drug product. Generic and 505(b)(2) pathways are more relevant than the biosimilar pathway.

What excipient innovation could most improve ZYNRELEF economics?

A formulation that preserves 72-hour analgesia while improving room-temperature stability, manufacturing throughput, application control, or storage logistics would have the clearest commercial value.

Why does the ZYNRELEF container and applicator matter?

The product’s viscosity, sterility, local retention, and surgical application requirements make container closure and delivery hardware part of product performance. A better applicator could reduce waste, preparation time, and dosing variability.

References

1. U.S. Food and Drug Administration. (2024). ZYNRELEF (bupivacaine and meloxicam) extended-release solution prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). FDA approves expanded use of ZYNRELEF for postsurgical pain. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Pacira BioSciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2021). FDA approves ZYNRELEF for the treatment of postsurgical pain. FDA.